Group 1 - The core theme of the event is "Medical Health Full-Scenario Intelligent Systems," showcasing five major industry intelligent systems by Zhongkang Technology [1] - The drugstore intelligent system and commercial intelligent system attracted significant attention with immersive experience zones, highlighting Zhongkang's leading position in the AI healthcare sector [1] Group 2 - Zhongkang Technology officially released a major upgrade plan for the Zhongkang Drugstore Intelligent System, focusing on five core intelligent systems for collaborative evolution [2] - The upgrade aims to transform the drugstore model from a simple medication provider to a "smart health steward," marking the entry of the pharmaceutical retail industry into an "algorithm-driven" era [2] - The full-chain AI decision-making system is constructed based on vast industry data, enhancing operational insights, member management, product improvement, staff empowerment, and disease management [2] Group 3 - Zhongkang Technology introduced a product matrix of commercial AI intelligent systems, including super individual intelligent systems, AI digital marketing growth platforms, and industrial marketing digital foundations [3] - The solutions empower pharmaceutical companies across marketing decision-making, sales execution, and terminal operations, achieving a sevenfold efficiency increase [3] - The complete value closed loop covers data governance, intelligent applications, and business implementation, redefining digital transformation standards in the pharmaceutical industry [3]

Group 1 - The core point of the news is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 66,200 shares at an average price of HKD 53.8841 per share, resulting in a total investment of approximately HKD 3.5671 million [1] - After the purchase, E Fund's total shareholding in Tiger Med reached 14.8183 million shares, increasing its ownership percentage from 11.98% to 12.04% [1]

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 1.1816 million shares at an average price of HKD 55.9087 per share, totaling approximately HKD 66.0617 million [1] - After the purchase, E Fund's total shareholding in Tiger Med increased to 13.8033 million shares, raising its ownership percentage from 10.25% to 11.21% [1][2]

Group 1 - Shanghai Mixine Pharmaceutical Technology Development Co., Ltd. has been established with a registered capital of 10 million yuan [1] - The company is wholly owned by *ST Sailong, indicating a potential strategic alignment or investment focus [1] - The business scope includes a variety of services such as technology development, medical research, food sales, and the production and sales of medical devices [1] Group 2 - The company is authorized to engage in the production and wholesale of pharmaceuticals, as well as the import and export of drugs [1] - The operational activities are subject to approval from relevant authorities, ensuring compliance with regulatory standards [1] - The company’s activities also encompass market research, marketing planning, and various consulting services [1]

Group 1 - The company, Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., has recently obtained CE certification for five of its products, allowing them to be sold in the EU and European Economic Area (EEA) markets [1] - The certification will facilitate entry into other international markets that recognize or reference EU standards, thereby broadening the overseas application scenarios for the company's products [1] - The company has also secured market access qualifications in multiple countries and regions, including Japan, Ukraine, Ecuador, and Vietnam, and plans to accelerate its international expansion [1]

| 1255 | 铸造有法见的磷业传 泰格仁达(上海)医药科技有限公司 | | 0 道一下 | ■ 应用 · | 企业中心 | E 10 | × 5VIP 骨贤服务 | | --- | --- | --- | --- | --- | --- | --- | --- | | 基本信息 6 | 法律诉讼 | 经营风险 | 经营信息 企业发展 | | 知识产权 | | MP 历史信息 ( | | 统一社会倡用代码 | 91310105MAERKQJP28 | 企业各称 | 颜格仁达(上海)医药科技有限公司 | | | | | | | | 登记状态 | 存法 | 成立日期 | 2025-07-28 | | | | 法定代表人 | 费观看 关联企业 57 | 注册资本 | 200万元 | 女被避手 | = | | | | 组织机构代码 | MAERKQJP-2 | 工岗注册号 | 310105000905104 | 纳税人旧别号 | | 91310105MAERKQJP28 | | | 企业类型 | 有限责任公司(非目然人投资成控股 的法人般资) | 實业明顯 | 2025-07-28 至 2045-07-27 | 的 ...

Core Points - The legal opinion letter confirms the legality of the convening and voting procedures of the second extraordinary general meeting of shareholders of Proris (Shanghai) Pharmaceutical Technology Development Co., Ltd. in 2025 [2][6] - The meeting was convened by the board of directors and held on July 21, 2025, with a combination of on-site and online voting [3][5] - The total number of shareholders present at the meeting was 126, representing 41,496,106 shares, which accounted for 52.1947% of the total shares [5] Meeting Procedures - The meeting was called by the board of directors and the notice was published on the Shenzhen Stock Exchange and other platforms on July 5, 2025 [3][5] - The meeting was held at the World Trade Center in Shanghai and was presided over by the chairman of Proris, Lai Chunbao [3][5] - Voting was conducted through both on-site and online methods, with specific time slots allocated for online voting [3][5] Voting Results - The first resolution regarding participation in the auction and establishment of real estate equity and corresponding debt was approved with 41,400,571 votes in favor, representing 99.7698% of the votes [6] - The second resolution concerning financial assistance to a proposed equity investment company was also approved with 41,374,691 votes in favor, representing 99.7074% of the votes [6] - The voting process was monitored and verified, ensuring compliance with legal and regulatory requirements [6]

Group 1 - The core point of the news is that Norsg (Beijing) Pharmaceutical Technology Co., Ltd. has applied for a patent for an automatic patient information processing system and method, which aims to enhance the accuracy of clinical drug trials and ensure patient safety [1] - The patent application was filed on June 2025, and the public announcement number is CN120260781A [1] - The method described in the patent involves several steps, including gathering historical case information, selecting suitable trial patients, assessing their safety levels, and categorizing trial data [1] Group 2 - Norsg (Beijing) Pharmaceutical Technology Co., Ltd. was established in 2008 and is based in Beijing, focusing on research and experimental development [2] - The company has a registered capital of 96.581256 million RMB and has made investments in 7 enterprises [2] - Norsg has participated in 10 bidding projects and holds 7 trademark registrations and 2 patent registrations, along with 3 administrative licenses [2]

Group 1 - The company held its 13th meeting of the third Supervisory Board on July 4, 2025, with all three supervisors participating, confirming the legality and validity of the meeting [1][2] - The Supervisory Board unanimously approved a resolution to participate in the auction for a 45% stake and corresponding debt of He Li Real Estate, aiming to improve operational efficiency and address office space constraints [1][2] - The company plans to acquire the real estate located at 1010-1016 Wai Ma Road, Huangpu District, Shanghai, with a land area of 1,492.20 square meters, to enhance its office space [1] Group 2 - The Supervisory Board also approved a resolution to provide financial assistance to He Li Real Estate, which has a good credit standing and low default risk, ensuring no harm to the company's main business or shareholder interests [2] - The financial assistance will be in the form of loans to support He Li Real Estate's daily operations and development [2]

Meeting Information - The company will hold its second extraordinary general meeting of shareholders on July 21, 2025, at 14:50 [1] - Network voting will be available on the same day from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 through the Shenzhen Stock Exchange trading system [1] Voting Procedures - Shareholders can choose between on-site voting or network voting, but not both; the first vote will be considered valid in case of duplicate voting [2] - Shareholders must be registered by the cut-off date of July 14, 2025, to participate in the meeting [2][3] Registration Details - Individual shareholders must present identification and stock account information for registration; authorized representatives must provide additional documentation [3][4] - Remote shareholders can register via email, fax, or mail, with a deadline of July 17, 2025, at 17:00 [4] Voting Process - All proposals for the meeting are non-cumulative voting proposals, and shareholders must indicate their voting preference as agree, oppose, or abstain [5][8] - Specific procedures for voting through the Shenzhen Stock Exchange trading system and internet voting system are provided [5] Additional Information - The company has provided templates for the authorization letter and shareholder registration form in the attachments [6][8]